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X ENOTRANSPLANT A TlON requires the suppres-
sion of vigorous humoral as well as cellular immune 
responses. FK 506. which has been used successfully for 
clinical allotransplantation of a variety of organs, I inter-
feres with the signal transduction pathway in T cells. For 
hamster to rat xenotransplantation in this study, FK 506 
was combined with antiproliferative drugs, which inhibit 
DNA synthesis required for expansion of both T- and 
B-cell clones. 
MATERIALS AND METHODS 
Animals and Operation 
Inbred male Lewis rats (LEW, RTlI) and Golden Syrian hamsters 
were used as recipients and donors, respectively. Heterotopic 
abdominal heart transplantation was performed by the method of 
Ono and Lindsey.2 Liver transplantation was performed accord-
ing to Kamada's method.) Rejection was diagnosed by the cessa-
tion ofthe heart graft beat or by the liver recipient death. followed 
by the histopathological examination. 
Immunosuppressive Agents 
Intramuscular FK 506 (Fttiisawa Pharmaceutical Co, Osaka, 
Japan) was given as a baseline immunosuppression. The dose for 
heart xenograft recipients was 2.0 mg/kg/d on days 0 to 5, followed 
by 1.0 mg/kg/d on days 6 to 30. Liver xenograft recipients were 
given 1.0 mg/kg/d on days 0 to 30. After 30 days out to day 100, 
both liver and heart recipients received FK 506 at a dose of 0.5 
mg/kg every other day. 
Antiproliferative drugs combined with FK 506 were Brequinar 
(BQR; Du Pont Medical Products. Wilmington. Del). RS-61443 
(RS; Syntex Inc). Mizoribine (Asahi Chemical Industry Co. Ltd), 
azathioprine, cyclophosphamide. and methotrexate. These drugs 
were prepared daily and administered orally by daily gastric 
installation. The antimacrophage agent deoxyspergualine (DSPG; 
Bristol-Meyers Squibb Pharmaceutical Research Institute) was 
administered intramuscularly. 
Antibody Analysis 
Antibody analysis was with the complement-fixing Iymphocyto-
toxic antibody assay described by Terasaki.4 The titer was defined 
as the highest serum dilution at which more than 50% of the 
hamster lymphocytes were lysed. For indirect immunofluores-
cence studies. frozen hamster liver sections were incubated with 
sera obtained from hamster xenograft recipients. followed by goat 
anti-rat immunoglobulin G (lgG) or IgM to detect the heterospe-
cific antibodies. 
RESULTS 
Heart Xenograft Survival 
Untreated xenografts were rejected in 3 days. FK 506 
alone prolonged the survival by I day. BQR, RS, mizor-
ibine. methotrexate. and DSPG were more effective as 
monotherapy, but the prolongation of xenograft survival 
was limited to 4 to 15 days with nearly toxic doses. 
Cyclophosphamide alone consistently prolonged the heart 
graft survival for more than 30 days with daily doses of to 
or 15 mg/kg. . 
When baseline FK 506 treatment was combined with a 
short course (9 to 30 days) of antiproliferative drugs, 
xenograft survival was enhanced in all drug combinations. 
Enhancement of survival was dramatic with cyclophos-
phamide. BQR. and RS, with routine survival beyond 100 
days for almost all grafts. Mizoribine, methotrexate. and 
DSPG were moderately effective as adjuvant agents. but 
azathioprine in toxic dose allowed only a slight prolonga-
tion of graft survival when used with FK 506. 
liver Xenograft Survival 
Untreated animals died within 8 days. Used as monother-
apy, FK 506 increased the median survival to 34.5 days. 
When used alone. the antiproliferative drugs slightly pro-
longed the median survival, which was 9 days with 7.5 
mg/kg of cyclophosphamide and 19 days with 3.0 mg/kg 
BQR. 
Animal survival was remarkably enhanced by combin-
ing these drugs with baseline FK 506. Cyclophosphamide, 
BQR, or RS for 10 to 14 days permitted long-term survival 
(> 100 days) for 80% to 90% of the animals under contin-
uous FK 506. Success rate was reduced to 15% to 40% 
when anti proliferative drugs were continued for 30 days or 
more. 
Anti-Hamster Antibodies 
After heart grafting, the increase of lymphocytotoxic anti-
bodies, which reached 256-fold to 512-fold in untreated 
animals on postoperative day 3, was suppressed in animals 
treated with induction therapy with antiproliferative drugs 
(BQR, RS, or cyclophosphamide for 30 days) combined 
with FK 506. Cytotoxic antibody titer after liver xe-
notransplantation was to times higher than after heart 
grafting, and this increase was only partially inhibited in 
animals with combined treatment. However, indirect im-
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munoftuorescence IgM deposition was lighter and less 
blood vessel directed in combined treatment. 
DISCUSSION 
A variety of treatment strategies have been tried to treat 
hamster to rat xenotransplantation. Total lymphoid irradi-
ation combined with cyclosporine A (CyA)' or DSPG,6 
and Cy A combined with cobra venom factor7 have been 
partially effective to treat hamster to rat cardiac transplan-
tation. As shown in this stud~I combination of FK 506 and 
antiproliferative drugs, which inhibit cell proliferation 
through the inhibition of key enzymes for de novo purine 
and pyrimidine nucleotide biosynthesis, was effective to 
break down the antibody barrier to xenotransplantation . 
Among antiproliferative drugs used with FK 506 in this 
study, BQR, RS, or cyclophosphamide routinely permit-
ted successful heart and liver xenotransplantation. Once 
the antibody barrier had been broken down, antiprolifera-
tive drugs were no longer necessary, and FK 506 alone 
was sufficient to maintain the xenograft function. These 
results are clinically applicable to prevent xenograft rejec-
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tion in humans. After completing these studies, it was 
learned that Hasan et alB had demonstrated a pronounced 
prolongation of heart xenograft survival with cyclophos-
phamide-Cy A therapy. 
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